Trileaflet setback cuts AoTtech value
This article was originally published in Clinica
Scottish company AorTech has blamed unspecified "performance issues" that emerged during preclinical trials for delays in further trials of its novel biocompatible polyuretheane trileaflet heart valve, the New Valve. The hold-up, announced last week, wiped almost a third off the value of the Bellshill, Lanarkshire company as shares dropped to 21p ($0.30). Tests on the product, which AorTech hopes will give it a share of the $800m worldwide heart valve market, may take another four months to complete.
You may also be interested in...
The company will use the proceeds to fund clinical trials, expand commercialization of its targeted radiation therapy, and file for CE marking in Europe.
Advanced Medical Solutions said it will buy Raleigh Adhesive Coatings for £22m ($29m) in cash to strengthen its overall wound care business.
While Amgen said the Phase III GALACTIC-HF results for omecamtiv mecarbil did not meet its high expectations for the heart failure candidate, Cytokinetics sees a path to treating certain patients.